Wyss Zurich’s Post

Exciting progress in the fight against #lymphedema! Swiss-based Lymphatica Medtech has secured €17.9 million in Series B funding to accelerate the clinical development of #LymphoDrain, a pioneering implantable device for lymphedema treatment. Here’s why this is a big step forward: Game-Changing Innovation: LymphoDrain is the first device of its kind—minimally invasive and designed to actively replace the lymphatic draining function, offering a much-needed option for patients. Strong Investor Support: Major backers like Panakes Partners, TechWald Holding S.p.A., and CDP Venture Capital SGR are investing in the vision. It’s great to see investor confidence behind a technology that could transform lives. Expanding Reach: With a new subsidiary in #Italy, Lymphatica is scaling up R&D, manufacturing, and clinical operations to bring this technology to those who need it most. Experienced Leadership: Industry expert Dan Rose joins as Chairman, bringing valuable experience to guide Lymphatica's growth. Meeting a Huge Need: Lymphedema affects over 10 million people globally, and treatment options are limited. LymphoDrain has the potential to be a transformative solution for millions. “We are thrilled to have closed our Series B financing, which will enable us to advance the clinical development of our groundbreaking technology for lymphedema patients,” said Dr. Marco Pisano, CEO and co-founder of Lymphatica Medtech. “With the support of our investors and new board members, we are one step closer to delivering a transformative solution that will significantly improve the lives of those suffering from lymphedema.” Valentina Triacca, COO and co-founder of Lymphatica Medtech, added: “Millions of people live with chronic lymphedema, and current treatment options fall short of providing effective relief. This investment allows us to continue advancing our LymphoDrain device, which has already shown promising results in a pilot feasibility study.” Alessio Beverina, Managing Partner at Panakès said: “Lymphatica is addressing a massive unmet medical need, with over 10 million people affected by lymphedema. This technology has the potential to transform the lives of those patients.” Dr. Lukas GUENTHER, CIO of TechWald added: "With its technology, Lymphatica is well-positioned to bring true sustainable clinical innovation in the treatment of lymphedema, greatly benefiting patients, physicians, and healthcare systems in various countries around the world." #LymphedemaCare #MedTechInnovation #HealthTech #SeriesBFunding #PatientCare #HealthcareSolutions #dubai #Uae #Medtech #digital #Innovation

PulmoBioMed, a spin-out from Northumbria University, has secured £1.4 million in funding to support the commercialisation of its innovative lung test, potentially enabling earlier diagnosis of asthma and other respiratory conditions. The funding round was spearheaded by the North East Venture Fund, backed by the European Regional Development Fund and managed by Mercia Ventures. Contributors included Northumbria University, SFC Capital, and private investors from the USA, EU, and UK. Additionally, PulmoBioMed secured a £700,000 grant from Innovate UK to showcase the advantages of its technology. PulmoBioMed's breath sampling innovation offers a non-invasive method for obtaining deep lung fluid samples, free from contamination by oral fluids. Traditional sampling tools struggle to differentiate between the two sources, potentially leading to ambiguous diagnoses. Conversely, invasive methods are infrequent and prone to environmental contamination. As a result, patients often face delays in receiving accurate diagnoses and effective treatments.

Rosetta Omics supports HealthTech Innovation Days (HTID) - 6th edition. I will be presenting Rosetta Omics to investors and other stakeholders. Every year, HealthTech For Care organizes the HealthTech Innovation Days (HTID), a pivotal European event serving as a platform for innovation and health stakeholders. HTID accelerates the implementation of solutions for patients, placing their role at the heart of innovation. The event fosters dynamic interactions among European companies, global investors, industrial and pharmaceutical groups, as well as patients and patient associations. Moreover, HTID includes conferences addressing crucial topics of general interest, guided by international experts and key opinion leaders (KOLs).   It takes place this year in Paris, on September 16th, 17th and 18th. On this website, you will find all practical informations, the agenda of the 2.5 days: https://lnkd.in/ezqainVi   Participating in HTID will allow participants to book 1x1 meetings with investors and pharma, listen to hot topic discussions with experts and KOLs, enjoy workshops in small groups and/or discuss with some patient associations in a dedicated space.   This event is European and brings together the entire value chain of the health industry. Great job Sophie Villedieu Pierre Courteille Maryvonne Hiance Angélique Introini Bpifrance Agoranov Medicen Paris Region Paris Saclay Cancer Cluster (PSCC) France Biotech Choose Paris Region CCI Paris IdF Région Ile de France EIT Health EIT Health France La French Tech ESCP Business School European Commission European Innovation Council and SMEs Executive Agency (EISMEA) Hello Tomorrow Les Deeptech 🚀 Agence de l'innovation en santé

Switzerland’s #biotech sector is experiencing unprecedented momentum, as industry leaders continue to make strategic moves that solidify their standing in the global market. This week’s updates underscore the sector’s strength, driven by cutting-edge innovation, substantial funding rounds, and deepening international collaborations. Here’s our overview of this week's highlights: MoonLake Immunotherapeutics (NASDAQ: MLTX) raised CHF 415M in follow-on financing to accelerate treatments for inflammatory diseases. Alentis Therapeutics secured CHF 105M to advance its cutting-edge research in oncology and fibrosis, cementing its leadership in these critical areas. Noema Pharma continues its mission to address neurological diseases, raising CHF 103M in Series B funding to expand its clinical pipeline. Rejuveron Vascular Therapeutics AG raised CHF 75M in Series B funding, focused on healthy aging and regenerative medicine, an area gaining increasing global attention. CRISPR Therapeutics and Vertex Pharmaceuticals push forward with gene-editing technologies for sickle cell disease, showcasing the power of collaboration in precision medicine. Oculis successfully raised USD 144M via a SPAC deal on NASDAQ, furthering its innovative solutions in ophthalmology. Santhera Pharmaceuticals finalized a CHF 1B acquisition deal with Ironwood Pharma, signaling increased consolidation and focus on neuromuscular and respiratory disease treatments. 🌟 Swiss Startup Spotlight: Amarastesia LTD is pioneering new methods in skin regeneration, leveraging Switzerland’s innovation ecosystem to develop breakthrough therapies. Altiscreen is making waves with its early-stage cancer detection technologies, addressing a critical gap in global healthcare. With CHF 2B+ raised this year and a series of high-impact acquisitions and IPOs, Swiss biotech is poised for continued growth. As we look ahead to 2025, expect these companies to drive innovation and reshape the future of healthcare. 💡 Are you a biotech startup looking to scale? Let’s discuss how Vias Digital can help accelerate your growth with regulatory-compliant, data-driven marketing and communications strategies. #MarketingStrategy #HealthcareInnovation #Marketing #DigitalMarketing #Communications

Biweekly Zoom Meeting of Silicon Valley US Angels Investors and Startups. September 11, 2024. Silicon Valley US Angels Biweekly Meeting for Startups and Investors. CatalystXL AI-Driven B2B corporate digital experience platform Patternox Scanner for detecting precancerous skin deformations with the help of AI AIO The world's first all-in-one restaurant platform �without integrations Repair Biotechnologies First-in-class therapy to rapidly and dramatically reduce plaque in arteries Aatec Medical Inhalation therapies for respiratory inflammation and infections Red Arrow Therapeutics Novel technologies to turn "cold" cancer tumors into inflamed "hot" tumors

Get ready for an unforgettable event with our startups! 🌟 We can't contain our excitement about everyone joining us! Featuring over 300 speakers, 120 exhibitors, and 50 startups, Festival of Biologics offers you the newest research in the field, unparalleled networking opportunities, and the opportunity to meet innovative startups. We're thrilled to announce the participation of five dynamic startups at our upcoming Festival: MeCo Diagnostics is a venture-backed startup developing predictive biomarker tests to unlock low-cost, low-toxicity targeted therapy for cancer. Our Phase 2 study reveals our first-in-class test matches patients with early-stage luminal breast cancer to a highly effective repurposed therapy that is twice as effective as the best targeted therapy currently available. SonoBac, Inc. is a recent spinout from UCSD and the Salk Institute for Biological Studies and is building a platform to increase biomanufacturing titers across multiple model organisms. Their scalable platform starts with a high throughput screen provided as a service followed by implementation of sonogenetic technology at scale. SonoBac is committed to improving biomanufacturing production titers and is looking to partner with drug developers to implement sonogenetics technology. Scispot (YC S21) is the leading tech stack for modern biotech, designed to transform biotech companies into AI powerhouses. By offering a Gen AI-powered data infrastructure, Scispot has become the go-to toolkit for hundreds of digital biotech firms, providing a solid foundation for their growth. Oterus Biosystems, Inc. biosystems is driven to improve the efficiency of In Vitro Fertilization (IVF). Their platform technology enhances embryo implantation, aiming to increase success rates of IVF, a process often requiring multiple cycles and causing emotional and financial strain. We believe everyone, regardless of socioeconomic background, deserves a chance to build a family. ADVANCED PRENATAL THERAPEUTICS, INC. (APT) has received Breakthrough Medical Device Designation by the US FDA for its novel therapy in development to treat preeclampsia (PE), an unmet need and leading cause of maternal and fetal death worldwide. Don't miss them at Festival of Biologics San Diego! Register now to meet them in person 👉 https://lnkd.in/eVJxatT8 #festivalofbiologicsUSA #startups

🏆 Alumni & Incubatee #News This year, we have three spin-offs incubated by the TUW i2ncubator that have been selected as finalists for the S&B Award!  🎉 The spin-offs have been pushing forward with some groundbreaking innovations and a strong dedication to excellence. SuRF - enables the contactless measurement & analysis of signals in radio frequency (RF) chips with unmatched accuracy. Velaex Technologies - is developing a new form of cancer therapy based on an implantable system. This enables precise administration and dosing of active substances directly at the tumor site. Sisyphus - a perovskite-based catalyst that converts CO2 into synthesis gas, a crucial intermediate for e-fuel and green chemical production A round of applause to all the 10 amazing teams selected as finalists for the S&B Award and their well-deserved recognition!  👏 Read more here: https://lnkd.in/d5qGWXUG #SBAwardFinalists #Innovation #Entrepreneurship #ProudMoment

Venture Kick startup Lymphatica Medtech closes EUR 17.9 million funding round to drive Innovation in Lymphedema Treatment. Congratulations to team of founders Marco Pisano (CEO) and Valentina Triacca (CCO) with their great team! https://lnkd.in/g3vxb34i About: Lymphatica, a medical device company, has raised EUR 17.9 million in Series B funding to accelerate the development and validation of LymphoDrain, the first implantable system for treating chronic lymphedema. Lymphedema, a common side effect of cancer therapies, causes limb swelling, pain, and recurrent infections, impacting over 10 million people in Europe and the U.S. This investment will advance Lymphatica's breakthrough technology, which aims to locally replace the lymphatic drainage function, offering unprecedented benefits to patients and healthcare professionals, and improving the lives of millions worldwide. #VentureKick #MedTech #SwissStartups 

🎉 Celebrating the successful conclusion of our 10-week BioEntrepreneurship & Innovation (BEI) program, Module B! What an incredible journey it has been, culminating in outstanding final pitches from six innovative teams pushing the boundaries of healthcare and biotechnology. 🧬🔬 🎥 Want to experience the energy and innovation firsthand? Check out our summary video below! Our brilliant teams showcased groundbreaking solutions: 🧠 EchoNeura - Revolutionizing intracranial brain surgery with image-guided therapy led by Héctor Estrada 💊 EFProtBio - Tackling Parkinson's with novel drug targeting protein aggregation. led by Dimitri Scherbakov (Shcherbakov) 🧫 ESkin - Advancing medicine with genetically modified skin equivalents led by Michela Di Filippo, PhD, Marta Slaufova and Dr. Paulina Hennig 📊 EpiCheck - Transforming diagnostics through scalable epigenetic age prediction led by Jingran Zhuo 🔋 CT Therapeutics - Accelerating CAR immune cell therapy (Congratulations Thomas Look, Mengze (Margot) Stettler-Zhang, Tim Weber & Alexandra Siffert on the win! 🏆) 🔬 STATcovery - Innovating drug development with genetic biosensors led by Roman Medelin A heartfelt thank you to our distinguished jury members Liliane Brunner Halbach, Simon P. Hoerstrup, Theofanis Manolikas, and Gretchen van Steenwyk for their expert insights and invaluable feedback that will help shape these innovations. 🙏 To all our speakers who shared their wisdom and to every participant who brought their passion and dedication to the program - you made this journey truly remarkable. 💯 And of course, a special shoutout to our management team Andreea Loredana Cretu, Elias Meier, Jessica Plucain - masters of the delicate art of turning brilliant chaos into structured success! 🎭 Sometimes playing the "fun police" (someone had to do it 😉), but always with our teams' best interests at heart. The future of #lifesciences innovation looks brighter thanks to ideas like these! 💫 #BioEntrepreneurship #Entrepreneurship #Healthcare #Biotech #Innovation #StartUp #BioEntrepreneurship #LifeSciences #MedTech #BEIprogram

✨ AI is expected to create exceptional growth in the healthcare sector and strives to deliver “healthcare anywhere anytime” as well as addressing the dire labor shortages in healtcare services ✅. The technology is bound to revolutionize medicine and healthcare, addressing such pressing matters as the fight against cancer, autoimmune diseases and many rare illnesses 💥. These are compelling reasons for the AI.FUND to invest in the healthcare sector and has driven one of the latest investment decisions: Mindpeak 🚀. Founded in 2018 by Felix Faber and Dr. Tobias Lang in Hamburg, the startup is the leading provider of AI-powered pathology solutions and has just raised $15.3 million in a Series A funding round💰. This funding round was led by ZEISS Ventures and InnoVentureFund (IFB Innovationsstarter GmbH), with participation from AI.FUND and the European Innovation Council – an amazing lineup of investors and a very promising solution and team 👍🏻 .    Mindpeak's AI algorithms were among the first to be used for routine clinical diagnostics in both the U.S. and the EU💡 . The company's innovative solutions enable automated histological and immunohistochemical tissue analysis and help experts make more confident decisions. To date, more than 30,000 patient diagnoses have been supported using the AI solution. Biopharmaceutical companies also use this AI technology to predict the efficacy of certain cancer drugs and to enable targeted treatments. We are convinced: this AI will save lives based on German AI-technology and innovation 💚 .    While Mindpeak already has a cash-flow positive core business, the new investment will enable the company to further expand the commercialization of its breakthrough technologies across multiple geographies. Also, the funding strengthens the product development roadmap for AI-powered histopathology, supporting clinical laboratories and biopharma companies worldwide 🌎.   Recently, the company has expanded its product portfolio to include pathological analysis of additional organs, biomarkers and stains. Strategic partnerships with leading healthcare organizations such as Roche, as well as positive regulatory developments, further strengthen the company's position in the market. For further information check 👉🏻 https://www.mindpeak.ai   Ragnar Kruse Dr. John Lange Dr. Hauke Hansen Petra Vorsteher Ingo Hoffmann Fabian J. G. Westerheide #artificialintelligence #aination #industrialai #aifuture #aiinhealthcare #aiinnovation #medicaldiagnostics #digitaltransformation #germanpotential #germanytech #investmentopportunities #aiapplications #techleadership #aifund #germaninnovation #techstrategy #digitaleconomy #digitalization #startupecosystem #mindpeak